Scienza e Tecnologia
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
Dr Shams UL Arifeen, Regional Medical Director, Telix Asia Pacific said, "We are pleased to have commenced this study, which brings advanced PSMA-PET imaging one step closer for Chinese men with prostate cancer. With our strategic collaborator in the region, Grand Pharma, we would like to express our gratitude to Dr Yong He, principal investigator at Zhongnan Hospital of Wuhan University as well as his clinical research team, and the patients who will contribute to this important study."
The Asia Pacific region comprises approximately one third of the world's male population and includes many nations whose populations are ageing or increasingly adopting a more affluent, "Western-style" lifestyle, the two main demographic trends driving increasing cancer incidence rates. Consequently, the incidence of prostate cancer is increasing in many parts of the region.
In China , 115,000 men are diagnosed with prostate cancer each year, increasing by approximately 6% each year. In line with government policy supporting wider geographic access to nuclear medicine, the number of PET/CT cameras installed in China is forecast to reach 1,240 by the end of 2023, compared with 133 in 2010.
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix's lead product, Illuccix (TLX591-CDx), has been approved by the U.S. FDA, by the Australian Therapeutic Goods Administration, and by Health Canada. Telix is also progressing marketing authorisation applications for this investigational candidate in the United Kingdom and the European Union.
Grand Pharma is an international pharmaceutical company of technological innovation. Its core businesses cover three major areas, namely pharmaceutical technology, nuclear medicine anti-tumour diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology and biotechnology. Based on the pharmaceutical and biological industries, Grand Pharma focuses on the needs of patients, and take technological innovation as the driving force. In response to the unmet clinical needs, Grand Pharma will increase its investment in global innovative products and advanced technologies, enrich and improve its product pipelines, consolidate and strengthen its industrial chain layout, and fully leverage Grand Pharma's industrial strengths and R&D capabilities to provide more advanced and diverse treatment solutions to patients worldwide.
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com
Legal Notices
Logo - https://mma.prnewswire.com/media/1920208/4215398/TeliMain_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/first-patient-dosed-in-pivotal-phase-iii-study-of-tlx591-cdx-illuccix-for-prostate-cancer-imaging-in-chinese-patients-301898412.html